Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FemRx

This article was originally published in The Gray Sheet

Executive Summary

FemRx: Plans on launching its Diva laparoscopic morcellator for use with the firm's OPERA (Out-Patient Endometrial Resection/Ablation) system during the third quarter, Andrew Thompson, president and chief executive officer of FemRx said at the June 19 Dillon, Read & Co. Medical Technology meeting in New York City. During the fourth quarter FemRx plans on launching its Pearl technology, which allows OPERA equipment to be used with normal saline. In 1998 the company plans on introducing the StarLight, which will be "the smallest continuous flow resectoscope on the market," Thompson said. FemRx also is developing the Soprano cryothermic global ablation system, which the company hopes to introduce in 1999...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT008317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel